Streetbeat News

Products Services

CRS

Carpenter Technology announced that it will increase base prices by an average of 7% to 12% on new, non-contract orders across the majority of its premium products. The price increases will be effective with new orders placed after October 8, 2023.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2023 | 8:17 pm

AKRO

Akero Therapeutics, Inc. (NASDAQ:AKRO) will present the topline week 36 results from its Phase 2b SYMMETRY study on October 10. The study evaluates the efficacy of efruxifermin (EFX) in patients with compensated cirrhosis due to non-alcoholic steatohepatitis (NASH). The results will include histology and changes from baseline in non-invasive measures of fibrosis, glycemic control, and lipoproteins, as well as safety and tolerability.

Portfolio Pulse from Happy Mohamed

October 09, 2023 | 8:09 pm

CYRX

Be The Match BioTherapies and Cryoport have announced a partnership to accelerate the development of cell and gene therapies. The partnership will provide access to standardized and optimized apheresis collection, cryopreservation and bioprocessing processes throughout the U.S. and Europe.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2023 | 8:08 pm

BNBUSD

Binance (CRYPTO: BNB) has announced a new feature called Copy Trading for its futures products. This feature allows users to replicate the futures trading strategies of experienced traders. It will be initially available in a few eligible regions. Copy Trading has two modes, Fixed Amount and Fixed Ratio. Lead traders will receive a 10% share of the profits made by their copy traders and a 10% commission on the trading fees generated by them.

Portfolio Pulse from Khyathi Dalal

October 09, 2023 | 8:06 pm

LXRX

Lexicon Pharmaceuticals' heart failure treatment, INPEFA, has been approved by the FDA and will be listed as a preferred product on Express Scripts' Medicare national formularies from November 1, 2023. This will provide access to INPEFA for Express Scripts Medicare patients who meet the parameters of INPEFA's FDA-approved indication.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2023 | 8:03 pm

IMUX

Immunic has reported interim data from its Phase 2 CALLIPER trial of Vidofludimus Calcium in progressive multiple sclerosis. The 24-week data shows improvements in biomarker NfL across the overall patient population and all subtypes. The data also reinforces Vidofludimus Calcium's neuroprotective potential. Full brain volume data from the 467 patient cohort is expected in April 2025. The Phase 3 ENSURE program in relapsing multiple sclerosis is ongoing.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2023 | 8:02 pm

VTYX

Ventyx Biosciences announced positive results from its Phase 2 trial of VTX002. The drug achieved its primary endpoint of clinical remission with a high rate of complete endoscopic remission.

Portfolio Pulse from Bill Haddad

October 09, 2023 | 8:02 pm

ACXP

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) shares surged after the company announced the successful completion and early discontinuation of the Ibezapolstat Phase 2b trial for the treatment of C. difficile infection. The company will analyze the data and report topline efficacy results which will allow Acurx to advance it to Phase 3 clinical trials more quickly.

Portfolio Pulse from Ryan Gustafson

October 09, 2023 | 7:36 pm

LLY

VRTX

CNBC's Jim Cramer has highlighted Vertex Pharmaceuticals' development of a non-opioid drug, VX-548, to treat acute pain. The drug is in the late stages of development and is expected to disrupt the pain management market. Cramer's Charitable Trust has a vested interest in Eli Lilly And Co, primarily due to its drug, Mounjaro, which is expected to expand its approved uses to include obesity treatment by the end of the year.

Portfolio Pulse from Vandana Singh

October 09, 2023 | 6:28 pm

MRNA

NVAX

PFE

Novavax Inc has received FDA authorization for its updated COVID-19 vaccine, targeting the omicron subvariant XBB.1.5. Despite the delay in release compared to Pfizer Inc and Moderna Inc's vaccines, analysts are optimistic about Novavax's prospects. The company could benefit from improved logistics in the private market and the anticipated peak in COVID-19 vaccine demand this fall and winter.

Portfolio Pulse from Vandana Singh

October 09, 2023 | 6:23 pm